摘要
目的进展性脑梗死是临床常见脑梗死类型,患者预后较差,研究表明,中西医结合治疗有很好的效果。本研究探讨疏血通注射液联合巴曲酶治疗急性进展性脑梗死的临床疗效及对血清白介素-6(interleukin-6,IL-6)、超敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)水平影响。方法选择2018-01-03-2019-03-31安阳市第六人民医院收治的62例急性进展性脑梗死患者作为研究对象,按照年龄、性别和疾病史等比较接近的原则分为两组。对照组31例予以巴曲酶治疗,研究组31例予以疏血通注射液联合巴曲酶治疗。比较两组美国国立卫生研究院卒中量表(national institutes of health stroke scale,NIHSS)、巴塞尔指数(Barthel index,BI)、hs-CRP、IL-6、同型半胱氨酸(homocysteine,Hcy)、全血黏度和凝血酶原时间。结果干预后,研究组NIHSS评分为(9.81±1.36)分,低于对照组的(13.32±2.69)分,t=4.879,P<0.05;研究组BI评分为(62.41±6.78)分,高于对照组的(53.26±5.74)分,t=6.971,P<0.05。干预后研究组凝血酶原时间为(8.74±1.63)s,短于对照组的(11.74±2.41)s,t=4.587,P<0.05;研究组全血黏度为(7.34±1.57)mPa·s,低于对照组的(7.89±1.14)mPa·s,t=3.159,P<0.05。干预后,研究组IL-6水平为(19.82±2.47)ng/L,低于对照组的(25.61±2.79)ng/L,t=4.971,P<0.05;研究组hs-CRP水平为(13.17±1.58)mg/L,低于对照组的(18.97±1.43)mg/L,t=5.124,P<0.05;研究组Hcy水平为(11.15±1.41)μmol/L,低于对照组的(15.87±1.71)μmol/L,t=4.687,P<0.05。结论疏血通注射液联合巴曲酶治疗急性进展性脑梗死疗效确切,可显著降低炎症反应,改善血流动力学。
OBJECTIVE Progressive cerebral infarction is a common type of cerebral infarction in clinical practice.The prognosis of patients is poor.Some scholars have shown that Chinese and Western medicine combined therapy has a good effect.This article aims to explore the clinical efficacy of Shuxuetong injection combined with batroxobin for acute progressive cerebral infarction and the effects on serum interleukin-6(IL-6)and high-sensitivity C-reactive protein(hsCRP).METHODS A total of 62 patients with acute progressive cerebral infarction admitted to our hospital from January 3,2018 to March 31,2019 were divided into two groups according to the similar principle of age,gender and disease history.In the control group,31 patients were treated with batroxobin,and 31 patients in the study group were treated with Shuxuetong injection combined with batroxobin.It was compared the National Institutes of Health Stroke Scale(NIHSS),Barthel index,hs-CRP,IL-6,homocysteine(Hcy),all blood viscosity and prothrombin time between the two groups of patients.RESULTS After intervention,the NIHSS score of the study group was(9.81±1.36),lower than that of the control group(13.32±2.69),t=4.879,P<0.05.The BI score of the study group was(62.41±6.78),higher than that of the control group(53.26±5.74),t=6.971,P<0.05.After intervention,the prothrombin time in the study group was(8.74±1.63)s,shorter than that of the control group(11.74±2.41)s,t=4.587,P<0.05.After intervention,the whole blood viscosity in the study group was(7.34±1.57)mPa·s,lower than that in the control group(7.89±1.14)mPa·s,t=3.159,P<0.05.After intervention,the level of IL-6 in the study group was(19.82±2.47)ng/L,lower than that of the control group(25.61±2.79)ng/L,t=4.971,P<0.05.After intervention,the level of hs-CRP in the study group was(13.17±1.58)mg/L,lower than that in the control group(18.97±1.43)mg/L,t=5.124,P<0.05.After intervention,the level of Hcy in the study group was(11.15±1.41)μmol/L,lower than that of the control group(15.87+1.71)μmol/L,t=4.687,P<0.
作者
王燕
郭学义
WANG Yan;GUO Xue-yi(Department of Neurology,Sixth People′s Hospital of Anyang,Anyang 455000,P.R.China)
出处
《社区医学杂志》
2019年第16期987-990,共4页
Journal Of Community Medicine
关键词
急性进展性脑梗死
巴曲酶
疏血通注射液
白介素-6
超敏C反应蛋白
acute progressive cerebral infarction
batroxobin
Shuxuetong injection
interleukin-6
hypersensitive Creactive protein
